test
September 21st 2023
In the first article of a 2-part series, Jack Khouri, MD, discussed the challenges that come with the toxicity profile of selinexor and how physicians can manage these adverse events.
September 19th 2023
September 15th 2023
September 8th 2023
Teclistamab With Talquetamab Shows a Manageable Safety Profile in RRMM
June 12th 2023Yael Cohen, MD, discusses the main safety findings from the phase 1/2 RedirecTT-1 trial, which is evaluating the combination of teclistamab-cqyv and talquetamab for the treatment of patients with relapsed/refractory multiple myeloma.
Watch
Daratumumab-Based Maintenance May Improve PFS After Auto-HCT in Relapsed MM
June 9th 2023Treatment with maintenance daratumumab, with or without pomalidomide, led to a median PFS of 28.5 months in patients with relapsed multiple myeloma after undergoing salvage autologous hematopoietic stem cell transplantation.
Read More
Teclistamab Follow-Up Data Yields Consistent Results in Relapsed/Refractory Multiple Myeloma
June 9th 2023At 2-year follow-up, patients with relapsed/refractory multiple myeloma treated with teclistamab achieved a median progression-free survival of 12.5 months with a median duration of response of 24 months.
Read More
Rapid Responses Seen With Daratumumab Combo in RRMM Pretreated With Lenalidomide
June 9th 2023In patients with relapsed/refractory multiple myeloma who were previously treated with lenalidomide, the combination of daratumumab, ixazomib, and dexamethasone led to improved overall response rates.
Read More
Isatuximab Combination Shows Deeper Responses in R/R Multiple Myeloma
June 7th 2023In the second article of this 2-part series, Douglas Sborov, MD, discusses the relevant data that shows the benefit of giving patients with relapsed/refractory multiple myeloma isatuximab as part of a triplet therapy.
Read More
Managing Adverse Events With Selinexor in R/R Multiple Myeloma
June 1st 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Sumit Madan, MD, discussed with participants what challenges they face using selinexor in patients with relapsed/refractory multiple myeloma. This is the second of 2 articles based on this event.
Read More
Physicians Discuss Recommended Therapies for R/R Multiple Myeloma
May 18th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Sumit Madan, MD, and participants discussed the therapies listed on the National Comprehensive Cancer Network guidelines for patients with relapse after 1 or more prior lines of therapy. This is the first of 2 articles based on this event.
Read More
Dosing and Toxicity: Considerations for Administering Teclistamab in R/R Multiple Myeloma
May 10th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Shaji Kumar, MD, discussed with participants the key considerations of administering the bispecific T-cell engager teclistamab for patients with relapsed/refractory multiple myeloma.
Read More
MajesTEC-1 Results Show Efficacy for Teclistamab in Multiple Myeloma
May 9th 2023In a live virtual event, Jens Hillengass discussed the results of the MajesTEC-1 study and how teclistamab is used to treat patients with relapsed/refractory multiple myeloma. This is the second article in a 2-article series on this case.
Read More